镁信健康三闯港股：百亿估值光环下，盈利困局与现金流之考

Core Viewpoint - Magnesium Health's IPO application is seen as a desperate move to address liquidity issues amid a backdrop of continuous losses and regulatory risks, despite its previous status as a "unicorn" in the healthcare technology sector [2][4][10] Financial Challenges - The company reported a significant cumulative net loss of 810 million yuan from 2022 to 2024, with annual losses of 446 million, 288 million, and 76 million yuan respectively, despite revenue growth from 1.069 billion yuan in 2022 to 2.035 billion yuan in 2024 [5][14] - Cash and cash equivalents plummeted by over 92%, from a peak of 2.2 billion yuan at the end of 2021 to 170 million yuan by April 2025, indicating severe cash flow issues [5][14] - The company has been trapped in a cycle of borrowing, with interest-bearing bank loans rising to 260 million yuan by April 2025 after repaying 590 million yuan in 2024 [5][14] Business Model Concerns - The revenue structure is heavily reliant on low-margin "Smart Drug Solutions" (10.8% gross margin) and underperforming "Smart Insurance Solutions" (81.5% gross margin), which has hindered overall profitability [6][14] - The "Smart Insurance" business is significantly dependent on the "Hui Min Bao" insurance segment, which has seen a drastic slowdown in growth, with participation rates dropping from nearly 150% in 2021 to just 6% in 2023 [7][17] Compliance and Operational Risks - The company faced regulatory scrutiny, with its subsidiary fined 330,000 yuan for multiple compliance violations, highlighting internal control deficiencies [9][18] - Market confidence has waned, as evidenced by a drop in valuation from 10 billion yuan in 2021 to 11.68 billion yuan in 2023, with funding amounts decreasing by over 90% [9][19] Conclusion - The upcoming IPO is viewed as a potential lifeline for Magnesium Health, but its success hinges on addressing fundamental issues such as dependency on low-margin businesses and improving compliance and internal controls [10][21]